about
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.Three-dimensional microscopic analysis of clinical prostate specimens.Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer.Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancerSYK is a candidate kinase target for the treatment of advanced prostate cancer.Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.MET expression during prostate cancer progression.CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasisEpithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 ExpressionClinicopathological characteristics of glomeruloid architecture in prostate cancerThree-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patternsConcordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimensClinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy
P50
Q36021088-48C5942B-68AE-469A-A315-54BE0E91CB8BQ37022410-D9092356-32FF-4D49-B4C9-3F7B4F0295CFQ38379538-2A63C0F6-3B02-4B3E-9015-FC35620D1E02Q38867721-069DAB65-8BC3-4A72-AB78-6085B028117FQ38909020-F5734F98-26DA-40B1-B912-5FA9D41435BAQ38941178-FCF9F5C1-4801-492B-9D1D-710AFD1FF1F6Q39341456-6652C2A2-CF9C-44D3-879F-F2D89EA96F56Q39492431-5C047A13-2D5F-424D-9C9C-9A89E4ACC342Q41418443-B1BEF5E8-D864-4209-90CB-B2F5806760CDQ41459844-32B25327-1A62-4D75-B24D-AE7CCAE867DDQ47371215-0D88DFA9-FA8C-4052-B846-D4D4CBC62895Q48378257-55A59DBA-DFD3-4117-8461-C97A3A4D3CA0Q49587940-F180CE31-5376-4297-ACAC-CF05D83BF020Q53159761-93B46155-1ABB-4A92-ACA7-60555414D4A3Q54387640-E2091736-A0A1-444F-82B9-A657ADFA1382Q57804572-AB515185-BC68-4809-9CEA-F008527BDA44Q89157690-28F46C68-E1C8-47B8-9012-E87277A360E6Q89811279-71E3CE46-395A-4CA3-B401-94D5840D1806Q91429967-A2779C77-5BCA-4778-853C-EFC74BD0046EQ91688622-62E148B6-37C8-47EA-8A93-8620C51EE9AAQ92684452-8172CD6C-31B7-4C12-B844-EAA8FA9152F3
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Esther I Verhoef
@ast
Esther I Verhoef
@en
Esther I Verhoef
@es
Esther I Verhoef
@nl
type
label
Esther I Verhoef
@ast
Esther I Verhoef
@en
Esther I Verhoef
@es
Esther I Verhoef
@nl
prefLabel
Esther I Verhoef
@ast
Esther I Verhoef
@en
Esther I Verhoef
@es
Esther I Verhoef
@nl
P106
P1153
55975272700
P31
P496
0000-0002-2734-0254